ABM Therapeutics said that the first cancer patient has been enrolled and dosed with its lead candidate ABM-1310, a BRAF inhibitor, in a phase 1 clinical trial in the US.
According to the clinical-stage biopharma company, the BRAF inhibitor had shown superior properties in pre-clinical animal models.
The brain-penetrant small molecule is expected to be developed for the treatment of various malignant tumors and brain metastases.
Dr. Chen Chen – founder and CEO of ABM Therapeutics said: “Many cancer patients are affected by brain metastases, but current treatment options are limited. ABM-1310 significantly prolonged median survival time of brain metastases in preclinical models and is expected to be a new generation of BRAF inhibitors for the treatment of various malignant tumors and brain metastases.
“We have been at full speed conducting clinical development of ABM-1310 in the USA and hope to bring the potential therapeutic benefits to patients as soon as possible.”
The phase 1 trial of ABM-1310 is a multi-center, open-label study for testing the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of the small molecule in patients having BRAF mutant advanced solid tumor and BRAF mutant patients with brain metastases. The early-stage clinical trial of the BRAF inhibitor aims to determine the optimal dose for phase 1b/2 trials.
Dr. Charles Zhao – Chief Medical Officer of ABM Therapeutics said: “We have designed our Phase 1 trial to move efficiently through dose escalation and to increase the chance of seeing early signs of clinical activity by focusing on the BRAF mutant patient population. We look forward to producing important early clinical data to guide our future clinical development.
“Based on the preclinical potency of ABM-1310, we believe it could provide a profound benefit for patients in urgent need of new therapies as both a single agent and in combination with other therapies.”